|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
EP2857036B1
(en)
|
2003-01-31 |
2016-12-21 |
Mount Sinai School of Medicine of New York University |
Combination therapy for treating protein deficiency disorders
|
|
EP1877099B1
(en)
|
2005-04-06 |
2012-09-19 |
Genzyme Corporation |
Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
WO2008089403A2
(en)
|
2007-01-18 |
2008-07-24 |
Genzyme Corporation |
Oligosaccharides comprising an aminooxy group and conjugates thereof
|
|
CA2696699A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Protalix Ltd. |
Saccharide-containing protein conjugates and uses thereof
|
|
US7722865B2
(en)
|
2008-01-18 |
2010-05-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
CA2711590C
(en)
|
2008-01-18 |
2021-03-23 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
WO2009131698A2
(en)
*
|
2008-04-23 |
2009-10-29 |
Iowa State University Research Foundation, Inc. |
PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
|
|
WO2010056746A1
(en)
*
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
CN102369023A
(zh)
|
2008-12-16 |
2012-03-07 |
建新公司 |
寡糖-蛋白缀合物
|
|
TR201908314T4
(tr)
*
|
2009-02-20 |
2019-06-21 |
2 Bbb Medicines B V |
Glutatyon bazlı ilaç dağıtım sistemi.
|
|
JP5866117B2
(ja)
*
|
2009-04-06 |
2016-02-17 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
分子を送達するための方法および材料
|
|
EP3679942A1
(en)
|
2009-06-17 |
2020-07-15 |
BioMarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
US9194011B2
(en)
|
2009-11-17 |
2015-11-24 |
Protalix Ltd. |
Stabilized alpha-galactosidase and uses thereof
|
|
CA2790786C
(en)
*
|
2010-02-24 |
2019-09-24 |
Zymenex A/S |
Process for production and purification of recombinant lysosomal alpha-mannosidase
|
|
WO2011108451A1
(ja)
*
|
2010-03-01 |
2011-09-09 |
日本ケミカルリサーチ株式会社 |
遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
|
|
PT3103469T
(pt)
|
2010-06-25 |
2021-03-04 |
Shire Human Genetic Therapies |
Administração de agentes terapêuticos no snc
|
|
JP6073783B2
(ja)
|
2010-06-25 |
2017-02-01 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
|
|
KR20230159646A
(ko)
|
2010-06-25 |
2023-11-21 |
샤이어 휴먼 지네틱 테라피즈 인크. |
이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
|
|
US20110318324A1
(en)
*
|
2010-06-25 |
2011-12-29 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for cns delivery of b-galactocerebrosidase
|
|
LT2588130T
(lt)
|
2010-06-25 |
2016-12-12 |
Shire Human Genetic Therapies, Inc. |
Terapinės priemonės pristatymas cns
|
|
HRP20191923T1
(hr)
|
2010-06-25 |
2020-01-10 |
Shire Human Genetic Therapies, Inc. |
Postupci i sastavi za isporuku arilsulfataze a u cns
|
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
|
KR101883803B1
(ko)
|
2011-01-20 |
2018-07-31 |
프로탈릭스 리미티드 |
식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
|
|
JP5665065B2
(ja)
|
2011-04-28 |
2015-02-04 |
国立大学法人大阪大学 |
リソソーム病治療用医薬組成物
|
|
WO2012157136A1
(ja)
*
|
2011-05-19 |
2012-11-22 |
財団法人東京都医学総合研究所 |
リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途
|
|
TW201307563A
(zh)
*
|
2011-05-19 |
2013-02-16 |
Shire Human Genetic Therapies |
純化乙醯肝素－ｎ－硫酸酯酶之方法
|
|
US9387236B2
(en)
*
|
2011-06-10 |
2016-07-12 |
Prothera Inc. |
Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
|
|
CN103747807B
(zh)
|
2011-07-05 |
2016-12-07 |
比奥阿赛斯技术有限公司 |
P97‑抗体缀合物和使用方法
|
|
AU2012294673B2
(en)
|
2011-08-05 |
2015-11-26 |
Bioasis Technologies Inc. |
p97 fragments with transfer activity
|
|
US20140377244A1
(en)
|
2011-12-23 |
2014-12-25 |
Shire Human Genetic Therapies, Inc. |
Stable formulations for cns delivery of arylsulfatase a
|
|
KR20230066482A
(ko)
|
2012-03-07 |
2023-05-15 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
SMT202100136T1
(it)
|
2012-05-03 |
2021-05-07 |
Amicus Therapeutics Inc |
Regimi posologici per il trattamento della malattia di pompe
|
|
CA3140358A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
WO2014089487A1
(en)
*
|
2012-12-07 |
2014-06-12 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia
|
|
AU2014243816B2
(en)
|
2013-03-13 |
2019-01-31 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
JP6603227B2
(ja)
|
2014-02-03 |
2019-11-06 |
バイオアシス テクノロジーズ インコーポレイテッド |
Ｐ９７融合タンパク質
|
|
DK3107562T3
(da)
|
2014-02-19 |
2019-12-16 |
Bioasis Technologies Inc |
P97-ids-fusionsproteiner
|
|
AU2015252906C1
(en)
|
2014-05-01 |
2020-09-17 |
Bioasis Technologies Inc. |
p97-polynucleotide conjugates
|
|
CN114540327B
(zh)
|
2014-09-30 |
2026-03-24 |
阿米库斯治疗学公司 |
具有增强的碳水化合物的高强度酸性α-葡糖苷酶
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
KR20250007693A
(ko)
|
2015-12-30 |
2025-01-14 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병 치료용의 강화된 산 알파-글루코시다제
|
|
AU2017239641A1
(en)
|
2016-03-30 |
2018-10-18 |
Amicus Therapeutics, Inc. |
Formulations comprising recombinant acid alpha-glucosidase
|
|
TWI759291B
(zh)
*
|
2016-03-30 |
2022-04-01 |
美商阿米庫斯醫療股份有限公司 |
用於選擇高m6p重組蛋白之方法
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
EA039750B1
(ru)
*
|
2017-03-30 |
2022-03-10 |
Амикус Терапьютикс, Инк. |
Способ отбора рекомбинантных белков с высоким содержанием m6p
|
|
SMT202300187T1
(it)
|
2017-05-15 |
2023-07-20 |
Amicus Therapeutics Inc |
Alfa-glucosidasi acida umana ricombinante
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
US12258597B2
(en)
|
2018-02-07 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
JP2023507575A
(ja)
|
2019-12-20 |
2023-02-24 |
コデクシス， インコーポレイテッド |
操作された酸性アルファ－グルコシダーゼバリアント
|
|
EP4735591A2
(en)
*
|
2023-06-30 |
2026-05-06 |
Crosswalk Therapeutics, Inc. |
Engineered acid alpha-glucosidase variants
|